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HIV vaccineV3 loop is a major neutralizing determinant of the HIV-1 gp120. Using 3D structures of cholera toxin B
subunit (CTB), complete V3 in the gp120 context, and V3 bound to a monoclonal antibody (mAb), we
designed two V3-scaffold immunogen constructs (V3-CTB). The full-length V3-CTB presenting the complete
V3 in a structural context mimicking gp120 was recognized by the large majority of our panel of 24 mAbs.
The short V3-CTB presenting a V3 fragment in the conformation observed in the complex with the 447-52D
Fab, exhibited high-afﬁnity binding to this mAb. The immunogens were evaluated in rabbits using DNA-
prime/protein-boost protocol. Boosting with the full-length V3-CTB induced high anti-V3 titers in sera that
potently neutralize multiple HIV virus strains. The short V3-CTB was ineffective. The results suggest that very
narrow antigenic proﬁle of an immunogen is associated with poor Ab response. An immunogen with broader
antigenic activity elicits robust Ab response.ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Development and use of an HIV-1 (HIV) vaccine is arguably the
most effective and efﬁcient means to stop the spread of the AIDS
pandemic. However, numerous attempts to elicit protective immunity
to HIV havemet with limited or no success (Hanke et al., 2007; Francis
et al., 2003; Rerks-Ngarm et al., 2009). Elicitation of broadly reactive,
cross-clade neutralizing antibodies (Abs) with vaccine constructs has
been particularly difﬁcult despite the fact that it has long been
recognized that the envelope glycoprotein (Env) is the target of anti-
HIV neutralizing Abs (Zolla-Pazner, 2005; Lasky et al., 1986;
Matthews et al., 1986; Scheid et al., 2009; Corti et al., 2010).
Env spikes on the surface of the virion are trimers of gp120/gp41
complexes, with three noncovalently assembled gp41 subunits (Chan
et al., 1997) anchored in the virus lipid membrane and three gp120
subunits assembled around the gp41 core. The exact arrangement ofthese subunits in the spike remains to be resolved (Liu et al., 2008).
Functionally, gp41 drives the membrane fusion process, while gp120
mediates interactions with cellular receptors. The majority of Abs
generated against gp120 are nonneutralizing, either because their
binding does not prevent virus/cellular receptor interactions and
subsequent fusion or because their epitopes are inaccessible on the
trimeric spike structure (Parren et al., 1997a,b; Kwong et al., 2002).
Therefore, focusing the immune response on the regions of gp120 that
are known to bind neutralizing Abs may improve the efﬁcacy of
prophylactic vaccines.
An additional hurdle to vaccine development is the diversity of the
virus and the required induction of Abs that recognize a broad
spectrum of viruses in the many subgroups (clades) that make up the
HIV group M family that is causing the pandemic (Barouch, 2008;
McBurney and Ross, 2008).
The V3 region of gp120, while variable in sequence, possesses
conserved structural and immunologic features that induce neutral-
izing Abs (Gorny et al., 1993, 2002; Stanﬁeld et al., 2006; Bell et al.,
2008; Wu et al., 2006). Numerous human anti-V3 mAbs have been
produced and characterized, and while many of these mAbs are
narrow in their focus, several have broad cross-clade neutralizing
Fig. 1. The V3 peptide fragment (shown in magenta ribbon representation and sticks)
bound to the broadly neutralizing mAb 447-52D (light and heavy chains are shown as
green and yellow ribbons, respectively). Formation of a three-strand beta-sheet
composed of two strands of the heavy chain CDR3 hairpin and one V3 strand, as well as
tight binding of the conserved residue P313 in the GPGR motif at the tip of the loop can
be observed. All molecular graphics images were prepared in Molsoft ICM-Pro.
514 M. Totrov et al. / Virology 405 (2010) 513–523activity (Gorny et al., 2002, 2004, 2006; Binley et al., 2004; Bell et al.,
2008; Pantophlet et al., 2008; Zolla-Pazner et al., 2004, 2008).
Approximately 30% of viruses can be neutralized by anti-V3 Abs
(Binley et al., 2004; Gorny et al., 2006; Pantophlet et al., 2007; Corti et
al., 2010; Hioe et al., 2010). This may be because the exposure of the
V3 in the native gp120 trimer is limited due to masking by other parts
of the protein, such as V2 (Krachmarov et al., 2005, 2006; Barnett et
al., 2001;Walker et al., 2009; Honnen et al., 2007; Nyambi et al., 2008;
Wei et al., 2003), but V3may also be “unmasked” by binding of certain
ligands or antibodies (Mbah et al., 2001; Wu et al., 2008; Hioe et al.,
2009). A specially designed V3-based immunogen that could induce
high titers of Abs with binding modes and epitope speciﬁcities similar
to those of known broadly neutralizing anti-V3 mAbs may therefore
be valuable as a component of a vaccine against HIV infection.
Cholera toxin subunit B (CTB) and a family of closely related
bacterial proteins such as Escherichia coli enterotoxin are homo-
pentamers composed of relatively small subunits (∼100 amino acids).
The protein is highly immunogenic and has been used in fusion
constructs to enhance immunogenicity of target proteins (Martin et
al., 2001; Gonzalez et al., 1993; Yamamoto et al., 1997; Eriksson et al.,
2003; Matoba et al., 2006). The crystallographic structure of CTB has
been solved in the free state as well as in complex with oligosacchar-
ides (Merritt et al., 1997; Zhang et al., 1995). CTB is capable of
inducing mucosal immunity (McKenzie and Halsey, 1984; Czerkinsky
et al., 1989; Lipscombe et al., 1991), which is an uncommon and
highly desirable feature for an HIV vaccine because infection typically
occurs via mucosal route.
GM1 ganglioside binding is believed to be a major factor in the
immunogenic properties of CTB and related toxins. X-ray structures of
CTB reveal the oligosaccharide binding sites. The availability of this
structural information allows protein designwithout disruption of the
GM1 binding site, therefore preserving immunogenicity. Moreover,
CTB is nontoxic without the A-subunit present in the native toxin, and
thus, CTB is used as a component of an anticholera vaccine approved
for use in humans.
The pentameric structure of CTB results in the presentation of ﬁve
copies of each epitope on its surface. It has been suggested that
repetitive presentation of an epitope on an immunogen can induce a
stronger immune response, probably because such immunogens can
trigger oligomerization of B-cell receptors recognizing the epitope
(Cruz et al., 2004a,b). Thus, a combination of the attractive
immunogenic features of CTB and the gp120 V3 loop could result in
an immunogen that would induce a strong, broadly neutralizing
immune response against the HIV. Indeed, V3-CTB immunogen
constructs have been described previously, but they induced only a
very modest anti-V3 immune response (Backstrom et al., 1994;
Backstrom et al., 1995). However, this previously reported design did
not beneﬁt from the wealth of structural andmodeling data on gp120,
the V3 loop, and V3 in complex withmAbs that have become available
more recently (Stanﬁeld et al., 2004, 2006; Dhillon et al., 2008; Kwong
et al., 2000; Jiang et al., in press). Furthermore, our preliminary
analysis suggested that the short V3 fragments used for these
previously reported constructs may have left out important antigenic
determinants and that the insertion position on the CTB scaffold may
not have allowed the V3 fragment to form the hairpin conformations
recognized by several anti-V3 mAbs.
In the present study, we designed, expressed, and characterized
two V3-scaffold immunogen constructs based on CTB and the V3 loop
(V3-CTB) in which the V3 loop was integrated into the CTB scaffold
sequence. We investigated two strategies for constructing these V3-
CTB scaffold immunogens. In the ﬁrst approach, a full-length 35-
amino acid V3 loop was engrafted into CTB and used as an
immunogen to focus the immune response on V3. In the second
approach, we attempted to narrow further the focus of the immune
response on the epitope of anti-V3 mAb 447-52D. mAb 447-52D, like
essentially all other human anti-V3 mAbs, recognizes a region in thecrown of the V3 loop composed of ∼14 amino acids (Stanﬁeld et al.,
2004, 2006; Bell et al., 2008; Dhillon et al., 2008; Sharon et al., 2003;
Burke et al., 2009; Jiang et al., in press). In addition to the relatively
straightforward restriction of the polypeptide graft to the V3 fragment
that is known to interact with this mAb, the “short V3-CTB” construct
was designed to induce preferentially the conformation of the V3
fragment that is compatible with its binding to this mAb, i.e., the
conformation observed in the V3/mAb 447-52D complex (Sharon et
al., 2003; Stanﬁeld et al., 2004; Dhillon et al., 2008; Burke et al., 2009).
The design of these two immunogens allowed the direct comparison
of the effects of focusing the response on the entire V3 immunogenic
region versus focusing on the much narrower epitope recognized by a
particular mAb.
Results
Direct insertion, as opposed to the commonly used strategy of
fusion via a linker, allows an immunogen scaffold to impose restraints
on the termini of a loop. Appropriate choice of the insert length and
position may be used to preferentially induce the conformations of a
loop that expose the conserved epitopes. We reasoned that exposure
of the conformationally correct conserved epitopes of V3 should
induce a broadly neutralizing anti-V3 Ab response.
Available structural data on V3 complexes with neutralizing mAbs
suggest two different binding modes as well as the epitopes
associated with broad neutralization: (1) The complex of a V3 peptide
with mAb447-52D (PDB accession code 1Q1J) (Stanﬁeld et al., 2004)
indicates that the epitope consists primarily of the backbone atoms of
the crown of the V3 loop, which forms a beta-sheet structure together
with two strands of the elongated hypervariable CDR3 loop of the
mAb heavy chain (Fig. 1). (2) The complex of V3 with another anti-V3
mAb, 2219 (PDB accession code 2B1H) (Stanﬁeld et al., 2006) shows
that this mAb contacts mostly side chain atoms of V3, but the amino
acids involved are highly conserved in the V3 sequence, including two
positively charged side chains and four side chains that form a
hydrophobic cluster. In the present work, we investigated presenta-
tion of the entire V3 or focusing the antigen on the epitope of the ﬁrst
type.
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We scanned the polypeptide backbone in the X-ray structure of the
CTB scaffold (PDB accession code 3CTB) (Merritt et al., 1998) for
residue positions that would allow low RMSD superposition and
clash-free match with the termini of the V3 loop as observed in the
gp120 X-ray structure (PDB accession code 2B4C) (Huang et al.,
2005). The best clash-free match had an RMSD of 0.37 Å for the C, Cα,
Cβ, and N atoms of V3 residues N295 and N332 and the corresponding
CTB residues F42 and A46 (Fig. 2). Using the CTB and gp120 structures
superimposed on these residue pairs, a chimeric structure was created
that included the complete V3 loop with V3 terminal cysteines C296
and C331 (Fig. 3A) fused at the match points to the CTB, excluding the
CTB turn residues K43-G45. Constrained minimization of the chimera
model resulted in a structure that was essentially strain-free and
differed by only 0.19 Å backbone RMSD from the templates. Finally, a
complete pentamer was reconstructed by superimposing ﬁve copies
of the chimera model onto the different monomers in the X-ray
structure of pentameric CTB. The ﬁnal model was inspected to ensure
that the grafts were not interfering with pentamer assembly, that the
V3 loops projected into different segments of space around the
scaffold, limiting the likelihood of undesirable V3–V3 interactions,
and that the V3 inserts did not interfere with the GM1 binding site.
Design of a V3 crown insert in a conformation preferentially bound by
mAb 447-52D
We ﬁrst performed conformational searches of the loops compris-
ing, fromN- to C- terminus: (1) a single ﬂanking phenylalanine on the
N-terminus corresponding to the CTB scaffold's F42, (2) the V3 loop
fragment K305-A316 observed to bind to the Fab fragment of 447-52D
in the X-ray structure, (3) varying number of additional V3 residues,
and (4) CTB scaffold's G45A46 on the C-terminus. When two
additional V3 residues were included, a low-energy conformation
similar to the experimental mAb-bound V3 peptide structure was
found. This conformation and loop sequence (Fig. 3B) was used to
construct an initial model of the designed V3 crown-CTB protein
(hereafter referred to as “short V3-CTB”) and to recreate in silico its
putative complex with Fab 447-52D. Analysis of this initial complex
model suggested several needed point mutations in the construct:
CTB's K23 and E79 side chains were clashing with the hypervariable
loop of the mAb and were changed to smaller serine residues; F317 of
the V3 insert was replaced with a glutamate to reduce the exposedFig. 2. Match of the CTB scaffold (blue) and V3 loop base (green) in the gp120 structure
(gray). Close correspondence of the backbone traces of the two structures at the F42CTB/
N295gp120 – A46CTB/N332gp120 junction can be observed.lipophilic surface and to stabilize the loop via salt bridging with K305
on the adjacent V3 strand; ﬁnally, CTB's A46 was mutated to a
methionine in an attempt to ﬁll in a hydrophobic pocket that formed
at the base of the loop insert. After constrained minimization, a ﬁnal,
reﬁned model of the short V3-CTB construct/Fab complex was
obtained (Fig. 4). The model's V3 residues R306–R315 that participate
in Fab interaction could be superimposed onto the X-ray structure of
the peptide/Fab complex with a backbone RMSD of 0.42 Å (0.87 Å for
all heavy atoms). The pentameric complex model was also con-
structed to ensure that mAb interaction with each of the ﬁve V3 grafts
can occur simultaneously and independently.
The use of a small oligomeric scaffold and direct insertion of the V3
fragment into the scaffold's tertiary structure resulted in constructs
that had an exceptionally high fraction of their surface presenting
relevant epitopes: the V3 surface constituted 51% and 26% of the total
solvent accessible surface of the full-length V3-CTB and of the short
V3-CTB immunogens, respectively. We postulated that this high
proportion of V3 epitopes on the immunogen surfacewould result in a
highly focused Ab response. The two immunogens were expressed in
E. coli and puriﬁed (Fig. 5).
Reactivity of the two V3-CTB constructs with a panel of 24 anti-V3 mAbs
The results from ELISA binding assays in which anti-V3mAbs were
titrated from 0.01 to 10 μg/ml and tested for reactivity with full-
length, short, and wild type V3-CTB are presented in Table 1. For the
full-length V3 construct, very high (50% binding at≤0.01 μg/ml) to
high (50% binding at≤0.1 μg/ml) afﬁnity for 9 of 10 clade B-derived
mAbs and 7 of 14 non-clade B-derived mAbs was observed. Lack of
reactivity or weak binding by the remaining seven mAbs could be
attributed to their speciﬁcity for the GPGQ motif that is frequently
present in non-clade B V3, whereas the V3-CTB constructs used here
carried the GPGR V3 motif characteristic of clade B. These results
suggested that the full-length V3-CTB construct bears the relevant
epitope(s) recognized by the majority of anti-V3 mAbs and might be
capable of eliciting a broad range of anti-V3 Abs.
In contrast, the structurally focused short V3-CTB construct
exhibited a much more narrow binding proﬁle. Importantly, the
afﬁnity of mAb 447-52D for the short and full-length V3-CTB
constructs was similar, which validated the design of the former,
which had been guided by the X-ray structure of the complex of Fab
447-52D with the V3 peptide fragment. A few other mAbs, mostly
clade B-derived (391–95, 694/98, 2442), also retained virtually the
same afﬁnities as those that they had for the full-length V3-CTB
construct, but the large majority of the mAbs in the panel showed
little or no reactivity with the short V3-CTB construct. While X-ray
structures are not available for the other mAbs that exhibit high
afﬁnity to the short V3-CTB construct, we can hypothesize that they
utilize a binding mode similar to that of mAb 447-52D. Thus, the full-
length and short constructs represent successful rational designs,
correctly presenting the complete V3 loop and the epitope recognized
by mAb 447-52D, respectively.
Immunogenicity of the V3-CTB constructs
The V3-CTB constructs were evaluated for immunogenicity using
an immunization protocol described previously (Zolla-Pazner et al.,
2008, 2009) in which rabbits were primed three times with clade B
gp120 DNA and boosted twice with either the full-length or the short
V3-CTB construct. Sera from immunized rabbits were tested for V3
binding by ELISA using a V3 fusion protein consisting of the clade B V3
consensus sequence linked to the Fc fragment of rabbit IgG (Davis
et al., 2009). Sera were titrated at dilutions ranging from 1:20 to
1:50,000. Sigmoidal curves were generated using sera from animals
boosted with the full-length V3-CTB construct, and a geometric mean
titer for 50% binding (GMT50) of 1:535 was achieved by the sera from
Fig. 3. (A) Full-length V3-CTB amino-acid sequence (V3 loop insert is in bold). (B) Short V3-CTB where only the V3 crown (shown in bold) is inserted. Additional mutations are
introduced to enhance conformational stability of the insert (mutated positions are underlined).
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was not achieved with the sera from any of the animals boosted with
short V3-CTB, even when tested at 1:20, and thus, GMT50 could not be
calculated. The curves shown in Fig. 6 suggest that the GMT50 for the
animals boosted with short V3-CTB would be approximately two
orders of magnitude less than that for the animals boosted with full-
length V3-CTB.
Virus neutralization
In agreement with V3 binding data from ELISA experiments, sera
from animals immunized with the full-length V3-CTB construct
displayed stronger neutralizing Ab responses than animals immu-
nized with short V3-CTB. In Table 2, data are shown for the 50%
neutralizing titers (NT50) of the SF162 pseudovirus (psV) and
chimeric psVs carrying the consensus V3 sequences of clades B, F,
A/E, A1, AG, H, or C in the HIV-1SF162 envelope backbone. The data,
generated using the CD4+CCR5+CXCR4+ U87 cell line as target cells,
demonstrate that the Ab response when full-length V3-CTB was used
as a boost induced Abs that could recognize and neutralize the psVs
bearing the V3 loops from all of these different clades. In contrast, the
sera from rabbits boosted with the short V3-CTB construct only
neutralized the psV carrying the homologous clade B V3 loop, and at
titers approximately two orders or magnitude less than those in the
sera from the full-length V3-CTB-boosted animals.
Sera from the animals boosted with full-length V3-CTB were also
tested for their ability to neutralize psVs from the standardmulticlade
Tier 1 panel (Li et al., 2005) using the CD4+CCR+ TZM.bl cell line as
target cells. A pool of prebleed sera from these animals showed no
neutralizing activity (50% neutralizing titer b1:20) against the fourFig. 4.Model of the short V3-CTB construct (ribbon and transparent surface) in complex
with the Fab fragment of mAb 447-52D (magenta and blue ribbons for heavy and light
chains, respectively).psVs tested. In contrast, sera derived from each animal 2 weeks after
the second boost with full-length V3-CTB neutralized three of the four
psVs tested (MW965.26, Bx08.16, and BaL.26) and two of ﬁve sera
displayed neutralizing titers against the fourth psV (SS11961.1)
(Table 3). Fifty percent neutralizing titers ranged from 1:22 to 1:4437.
The immune sera were also tested for their ability to neutralize a
panel of primary isolates from clades B, A, and AG (Table 4). Sera from
rabbits immunized with the short V3-CTB construct had low
neutralization titers and failed to neutralize most viruses tested. For
example, the only virus that was convincingly neutralized was BZ167,
where four of ﬁve sera displayed a GMT50 of 1:18. In contrast, ﬁve of
ﬁve rabbits boosted with full-length V3-CTB neutralized BZ167 with a
GMT50 value 1:113. Neutralizing titers in sera of animals boosted with
the full-length V3-CTBwere detected against ﬁve additional viruses in
this panel. None of the sera in either groups neutralized any clade C
primary isolates (data not shown). Thus, the full-length V3-CTB
induced a stronger and broader neutralizing Ab response and induced
cross-clade neutralizing Abs.
T-helper epitopes in the two immunogens
To inform future immunogen design efforts, we investigated
further the potential determinants of immunogenicity for the two
constructs. We applied epitope prediction algorithms available from
the Immune Epitope Database and Analysis Resource (Peters et al.,
2005). MHC-II binding predictions were performed on both immu-
nogen constructs against multiple MHC alleles. Consensus percentile
ranks of three different prediction methods were utilized to score
putative epitopes (Bui et al., 2005; Nielsen, Lundegaard, and Lund,
2007; Sturniolo et al., 1999). Hits with low-consensus percentile ranks
that correspond to the likelihood of T-cell recognition are listed in
Table 5. An epitope inherited from the CTB scaffold was found in both
immunogens. A known T-cell epitope from the HIV V3 loop
(Bergmann et al., 1993) was detected in the full-length V3-CTBFig. 5. Analysis of purity of recombinant CTB immunogens. Puriﬁed recombinant
immunogens were analyzed by SDS–PAGE and stained with Coomassie. Lane 1:
molecular weight markers with corresponding molecular weights (kDa). Lane 2: wide
type CTB. Lane 3: full-length V3-CTB. Lane 4: short V3-CTB.
Table 1
ELISA titrations of mAb binding to two V3-CTB immunogen constructs and the wild type CTB control. mAbs listed in red were derived from non-clade B-infected subjects; those listed
in blue were derived from clade-B infected individuals. Each was tested at concentrations of 10 to 0.01 μg/ml on plates coated with 1 μg/ml of the designated form of CTB. Optical
densities from ELISA plates are shown and color-coded to designate strong (red) to no (white) binding. An irrelevant anti-parvovirus mAb (1418) does not bind to any of these
constructs (data not shown).
ig. 6. ELISA titration curves of immune sera vs. V3 fused to the Fc fragment of rabbit IgG. Immune sera were obtained two weeks after the second protein boost from rabbits
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designated as #6–10, boosted with the full-length V3-CTB (red-1), or from rabbits #1–5, boosted with the short V3-CTB (blue-).
Table 2
Reciprocal 50% neutralization titres (NT50) of sera from rabbits boosted with the short V3-CTB construct (rabbits 1–5) or the full-length V3-CTB construct (rabbits 6–10). Pseudoviruses
tested include the wild type SF162 and chimeric pseudoviruses carrying V3 sequences corresponding to the consensus sequences of clades B, F, A1, AE, AG, H and C. Neutralization titre
ranges are color-coded as grey, yellow. orange and red for NT50 b10,10–1000,1000–10000 and N10000, respectively.
518 M. Totrov et al. / Virology 405 (2010) 513–523construct. This epitope was missing in the short V3-CTB construct;
however, the short V3-CTB construct contained two additional
predicted T-cell epitopes: one emerged at the scaffold–graft junction
and the other was introduced serendipitously with the point
mutations intended to stabilize the construct and improve Ab binding.
In summary, evaluation of the existence of predicted T-cell epitopes
suggests that both constructs contain multiple T-cell epitopes and
comparable levels of T help activation can be expected. Because
evaluation of T-cell activity in rabbits is problematic, T-cell immuno-
genicity was not evaluated with cells from the immunized rabbits.
Immunogenicity of the scaffold
Given that multiple factors, such as protein stability and binding to
cellular receptors, may have affected the overall immunogenicity of
the constructs, we compared the anti-CTB scaffold Ab levels in the
sera of the two sets of immunized rabbits. ELISA data from sera
binding to CTB indicated that very similar levels of Abs against CTB
were elicited in the two groups: reciprocal GMT50 titers were 1.9×104
and 1.8×104 for the short and full-length V3-CTB immunized groups,
respectively. Therefore, it appears that the two constructs have
comparable overall immunogenicity.
Discussion
Extensive immunologic and viral studies have previously shown
that many anti-V3mAbs display cross-reactivity between V3 peptides
and gp120 proteins from diverse viruses of the different clades of HIV-
1 (Gorny et al., 1993, 2002; Binley et al., 2004; Pantophlet et al., 2008).
These studies demonstrated that, although by deﬁnition V3 is highly
variable in its sequence, this region of gp120 contains immunolog-
ically conserved elements. Immunologic data are further supported by
ﬁndings that, despite its sequence variability, V3 must retain certainTable 3
Reciprocal 50% neutralization titers (NT50) of sera from rabbits boosted with the full-
length V3-CTB construct. Pseudoviruses tested include those from the standard
multiclade Tier 1 panel as well as a negative control psV carrying the envelope of
murine leukemia virus (MuLV).
Clade C Clade B Clade B Clade B
Rabbit no. MW965.26 Bx08.16 BaL.26 SS11961.1 MuLV
6 28 105 125 22 b20
7 4437 129 171 25 b20
8 451 58 63 b20 b20
9 159 62 59 b20 b20
10 1206 103 148 b20 b20conserved structures to interact with the chemokine receptors on the
surface of target cells (Shioda et al., 1992; Trkola et al., 1996; Hill et al.,
1997; Labrosse et al., 2001; Cardozo et al., 2007). Moreover, the
conformational conservation of V3 is conﬁrmed by crystallographic
(Stanﬁeld et al., 2004, 2006; Bell et al., 2008; Dhillon et al., 2008;
Burke et al., 2009; Jiang et al., in press) and NMR (Sharon et al., 2003)
studies. This extensive literature was the basis of our initial use of the
V3 region of gp120 as an epitope for inducing Abs with broad
immunologic and antiviral activity.
In the present work, recombinant chimeric V3-CTB immunogens
were successfully designed using structural data, molecular modeling,
and protein engineering. The short V3-CTB form bound to mAb 447-
52D, whose epitope this construct was intended to mimic optimally.
The full-length V3-CTB bound to most anti-V3 mAbs, demonstrating
the success of the design in presenting the V3 epitopes as exposed,
correctly folded, Ab-accessible conformations. Use of these new
immunogens to boost the immune response of rabbits showed that
the full-length V3-CTB construct was able to induce V3-binding Abs
and Abs that display cross-clade neutralizing activity against psVs and
primary isolates. The full-length V3-CTB immunogen induced a much
stronger and broader Ab response than did the short V3-CTB.
The two V3-scaffold constructs that we have designed and tested
were based on the V3 loop found in clade B viruses. These were used
because much of the immunologic and structural data were based on
studies of the clade BV3 loop.However, the clade BV3 loop is relatively
unusual among the HIV-1 group M virus clades because it contains a
GPGR rather than a GPGQmotif at its center (Leitner et al., 2005). Use
of the clade B V3 as the epitope in both the short and full-length V3-
CTB constructs studied here resulted in immunogens that were
relatively limited in their ability to induce Abs that neutralize psVs
and viruses carrying V3 loops that contain the GPGQ motif. Thus, for
example, the neutralizing titers of the sera from animals boosted with
full-lengthV3B-CTB, against the chimeric psV carrying the homologous
V3B, were two to three orders of magnitude higher than those against
chimeric psVs carrying heterologous V3 loops bearing the GPGQmotif
(Table 2). Our previously published work (Zolla-Pazner et al., 2009)
suggests that follow-up studies with full-length V3-CTB immunogens
where V3B is replaced by V3 sequences containing the GPGQ motif or
other rationally designed V3 loops will give rise to more broadly
reactive and perhaps higher titers of anti-V3 Abs.
As noted above, the use of CTB as a scaffold for the HIV-1 V3
epitope was based on scans of the Protein Data Base for molecules
with surface-exposed beta-turns that could be structurallymatched to
the beta-hairpin structure at the base or in the crown of the V3 loop.
Among the proteins found to have a suitable beta-turn, we further
looked for proteins that would form high-order oligomers, could be
easily expressed in bacteria, and for which some immunogenicity data
Table 4
Primary isolates neutralization. The serum from each animal was tested against each of the seven primary isolates listed. The 50% neutralizing titer for each serum/virus
combination is shownwhere 50% neutralization was achieved at a dilution of 1:10 or higher; all empty cells in the table denote little or no neutralization at a serum dilution of 1:10.
The yellow, green, and blue boxes denote group GMT50 values of 1:10–50, 1:51–100, and N1:100, respectively.
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because it has been used extensively as a component of vaccine in
humans to protect against cholera (marketed as Dukoral (Lopez-
Gigosos et al., 2007)) and has been tested as a scaffold for other
immunogens (Backstrom et al., 1994; Matoba et al., 2006).
We have previously shown that using an immunization regimen in
which animals are primed with gp120 DNA and boosted with a
scaffold immunogen carrying only the V3 epitope of gp120 is able to
focus the immune response on this neutralizing epitope and induce
cross-clade neutralizing Abs (Zolla-Pazner et al., 2008, 2009). In the
previous studies, the V3-scaffold immunogen consisted of various V3
loops fused to the C-terminus of a truncated form of the murine
leukemia virus gp70 (Kayman et al., 1994). This construct carried one
copy of V3 per molecule of gp70. In contrast, the V3-CTB immunogens
designed and tested in this study carries ﬁve copies of V3 per
pentamer of CTB. Although direct comparisons cannot be made
because immunizations were not conducted in parallel using exactly
the same immunization regimen, it would appear that full-length V3-
CTB is a better immunogen than full-length V3-gp70, giving Ab
responses of greater breadth and potency. The most direct compar-
ison can be made by analyzing the responses of rabbits #6–10,
immunized in this study with clade B gp120 DNA and boosted with
the full-length V3B-CTB (B/V3B-CTB) to those immunized in an earlier
study with the gp120 DNA from a clade A strain carrying a V3 loop
with the GPGR motif (Ar) and boosted with V3B-gp70 (Ar/V3B-gp70)
(Zolla-Pazner et al., 2008). The GMT50 for neutralization of V3
chimeric psVs averaged 10-fold higher in the rabbits receiving the
B/V3B-CTB vs. the Ar/V3B-gp70 regimen. This may be due to the
difference in the V3 valency of the immunogens (one for V3-gp70 vs.
ﬁve for V3-CTB) and/or to differences in modes of antigen
presentation and induction of B-cell maturation due to the differential
binding of these immunogens to cell receptors: CTB binds to
ganglioside GM1, mammalian cell wall glycosphingolipid widely
distributed in all tissues, whereas gp70 binds to mouse cationic amino
acid transporter (mCAT-1) (Albritton et al., 1993). Another differenceTable 5
Result of T-cell epitope predictions for the sequences of two immunogenic constructs.
Epitopes with lowest consensus percentile ranks (CPR) are shown.
Construct Sequence fragment Location MHC allele CPR (%)
Full-length YTTGEIIGDIRQAHC V3 DRB1-0301 0.9
Full-length and
short
EKLCVWNNKTPRAIA Scaffold DRB1-1302 0.9
Full-length and
short
Same as above Scaffold DRB1-0802 1.1
Short TQIHTLNNSITSYTE Mutated Scaffold DRB1-1302 0.1
Short REMAIITFKRIHIGP Junction DRB1-1501 0.29between the gp70 and CTB carriers is that the gp70-V3 proteins
contained N-linked glycans at the base of the V3 loop and at the
internal glycosylation site at position 6 of the V3 loop. The proximity
of this position to residues known to be included in V3 epitopes might
affect immunogenicity.
The inability of the short V3-CTB construct to elicit signiﬁcant Ab
tite. Irs underscores the challenge of designing effective recombinant
immunogens that direct the immune response towards a highly
restricted singular three-dimensional epitope. The poor performance
of the short V3-CTB construct may be explained by several possible
causes: (1) the rabbit Ab repertoire may not contain genes that are
appropriate to develop 447-52D-like Abs or (2) ﬂexibility of an epitope
loop may be required for immunogenicity. Further investigation would
be needed to establish the minimal essential epitope(s) within the
complete V3 that are sufﬁcient for a robust immune response, although
it is clear from previous studies that the length of V3 is not the only
critical variable that contributes to the induction of neutralizing Abs
(Yang et al., 2004). The limited efﬁcacy of previously described V3-CTB
constructs and other HIV epitope–scaffold immunogens for eliciting
neutralizing Abs (Backstrom et al., 1995; Backstrom et al., 1994; Law et
al., 2007; Muster et al., 1994; Eckhart et al., 1996) also highlights the
challenge of constructing effective recombinant immunogens that focus
the immune response on neutralizing epitopes.
In contrast, the immunogenicity data obtained after boosting with
the full-length V3-CTBunderscore the potential that optimally designed
immunogens can have in focusing the immune response on a
neutralizing epitope. The full-length V3-CTB induced cross-clade
neutralizing Abs in rabbits. Because the immunogen was rationally
designed, this result serves as an important initial point for immunogen
optimization for achieving the desired breadth and potency for a
protective Ab response. Importantly, a variety of V3 loop sequences and
structures can be placed on this scaffold to optimize the breadth and
potency of the Ab response. Moreover, this approach may serve as a
platform for designing other epitope–scaffold immunogens that will
induceAbs speciﬁc for additional HIV-1 neutralizing epitopes and/or for
protective epitopes against other pathogens.
Materials and methods
Design of the antigen constructs: full-length V3 graft
Conformation of the complete V3 loop in the gp120 context as
revealed by the X-ray structure (PDB code 2B4C (Huang et al., 2005))
was used as a prototype to identify grafting site(s) on the scaffold.
Coordinates of a pair of gp120 residues, N295 (immediately preceding
the cysteine bridge C296–C331) and residue N332 (immediately
following the bridge) were used to scan the CTB structure (PDB code
3CHB) (Merritt et al., 1998) for a pair of residues closely matching the
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a scaffold clash test: gp120, N295, and N332 were superimposed onto
identiﬁed residue pairs in CTB, and the resulting position of the V3
loop was checked for any clashes with the rest of the CTB scaffold.
When low RMSD and clash-free superposition were achieved, the
complete model of the chimeric protein was constructed in ICM using
a regularization procedure that threads an idealized polypeptide
chain through the template structures (Abagyan et al., 1994).
Design of the antigen constructs: short V3 crown graft
The fragment of V3 loop observed in the mAb 447-52D/peptide
complex structure (PDB) consists of a GPGR beta-turn and a beta-
strand segment that is N-terminal to the turn. Although the C-
terminal segment of the V3 crown is disordered in this X-ray
structure, experimental evidence from other structures (Sharon
et al., 2003) suggests that it has a strong propensity to form another
strand, thus completing a beta-hairpin. We reconstructed a low-
energy hairpin structure by BPMC global energy minimization in ICM
(Abagyan and Totrov, 1994). Initially unstructured N- and C-terminal
polypeptide segments of varying length were added to the residues
observed in the X-ray structure of the bound peptide (PDB code 1Q1J)
and subjected to Monte Carlo sampling. Residues corresponding to
I307-R316 observed in the X-ray structure and engaged in mAb
interaction were kept rigid. Terminal residues of the loop were
harmonically constrained to the positions of F42 and A46 in CTB
scaffold.
Preparation of the recombinant V3-CTB constructs
Wild type (WT) CTB (as control), the full-length V3-CTB and the
short V3-CTB genes were chemically synthesized and cloned into
pSUMO plasmids. Amino-terminally SUMO-tagged forms of CTB and
the two immunogen constructs were produced by induction of T7
RNA polymerase in E. coli strain BL21(DE3) containing pSUMO-CTB,
pSUMO-full-length V3-CTB, or pSUMO-short V3-CTB, respectively.
After adding IPTG to a log-phase culture grown in Luria–Bertani (LB)
medium, the cells were pelleted, resuspended, and lysed with a
French press. SUMO-tagged CTB and the two immunogen constructs
were puriﬁed from each of the resulting cultures by afﬁnity
chromatography on a Ni-nitrilotriacetate column. SUMO tags were
cleaved from the fusion proteins by a SUMO protease and removed by
a Ni-NTA column. Proteins were collected in the ﬂow-through and
dialyzed overnight. The puriﬁed proteins were stored at −80 °C.
Evaluation of binding of immunogen constructs to anti-V3 mAbs
Binding of the immunogen constructs to various anti-V3mAbswas
evaluated in an ELISA assay as previously described (Gorny et al.,
1997). Brieﬂy, immunogen constructs or wild type CTB were coated
onto plastic plates at 1.0 μg/ml and incubated overnight at 4 °C. The
next day, the plates were washed three times with wash buffer (1×
PBS with 0.05% Tween 20, pH 7.4) before incubation for 1.5 h at 37 °C
with human mAbs at concentrations between 0.01 and 10.0 μg/ml.
After washing, the plates were incubated with alkaline phosphatase-
conjugated goat anti-human IgG (Fc-speciﬁc) for another 1.5 h at
37 °C. Plates were washed again, and the substrate, p-nitrophenyl
phosphate in 10% diethanolamine, was added for 30 min. Plates were
read at 410 nm. Negative controls consisted of immunogen-coated
wells reacted with an irrelevant human mAb (anti-parvovirus).
Determination of anti-V3 rabbit serum ELISA titers
Titration of rabbit sera against a fusion protein consisting of V3
from clade B isolate JR-CSF fused to the N-termini of rabbit Fc
fragments (V3-rFc) was performed as previously described (Davis etal., 2009; Zolla-Pazner et al., 2009). Brieﬂy, V3-rFc was coated onto
plastic plates at 2.0 μg/ml and incubated for 2 h, followed by blocking
with 100 μl/well of 2.5% dry milk in phosphate-buffered saline for 1 h.
Serial two-fold dilutions of rabbit sera were prepared in 2.5% dry
milk/PBS and, after 2 h of incubation at 37 °C, bound serum Abs were
detected with goat–anti-rabbit Fab-speciﬁc, alkaline phosphatase-
conjugated secondary Abs (Zymed). Finally, the substrate, p-nitro-
phenyl phosphate (Sigma) in 10% diethanolamine, pH=9.8, was
added, and the plates were read at 405 nm.
Rabbit immunization
Immunizations were performed using a prime-boost protocol
previously described (Zolla-Pazner et al., 2008; Wang et al., 2006).
Brieﬂy, female New Zealand White (NZW) rabbits 6–8 weeks old
(with a body weight of ∼2 kg) were purchased from Millbrook Farm
(Amherst, MA) and housed in the animal facility managed by the
Department of Animal Medicine at the University of Massachusetts
Medical School in accordance with an IACUC-approved protocol.
Groups of rabbits ﬁrst received three DNA immunizations at weeks 0,
2, and 4 using a Bio-Rad Helios gene gun (Bio-Rad Laboratories,
Hercules, CA). The gp120 DNA vaccine plasmid or the negative
control pJW4303 vector plasmid was coated onto 1.0-μm gold beads
at a ratio of 2 μg of DNA per milligram of gold. Each gene gunshot
delivered 1 μg of DNA to a total of 36 nonoverlapping sites on the
shaved abdominal skin of each rabbit at each of the three priming
immunizations. The animals then received two boosts with individ-
ual V3-CTB proteins at weeks 10 and 14. A total of 100 μg per
injection of the V3-CTB immunogen were administered intramus-
cularly with IFA. Blood was collected before immunization and
2 weeks after each immunization.
Generation and neutralization of pseudoviruses
The expression vectors for chimeric forms of SF162 env with
various consensus V3 sequences were generated by introducing the
modiﬁcations sequentially by QuikChange site-directed mutagenesis
(Stratagene, La Jolla, CA), as described (Krachmarov et al., 2006). The
infectious pseudotyped viruses were generated by cotransfection of
293 cells with an env expression vector and with the complementing
vector pNL4-3.Luc.R-E- (NIH AIDS RRRP, catalog no. 3418, donated by
Dr. Nathaniel Landau). Transfections were performed in tissue culture
dishes using TransIT-LT1 Reagent (Mirus Bio Corporation, Madison,
WI) according to the manufacturer's protocol.
Neutralizing activity was determined as previously described
(Krachmarov et al., 2001) in a single-cycle infectivity assay using
virions pseudotyped with the molecularly cloned HIV env of interest.
In brief, psVs were incubated with two-fold serial dilutions of heat-
inactivated sera, starting at a dilution of 1:10, from immunized rabbits
for 1.5 h at 37 °C, and then added to 10,000–12,000 U87-T4-CCR5
target cells/well in 96-well plates in the presence of polybrene
(10 μg/ml). After 24 h, cells were re-fed with RPMI medium contain-
ing 10% FBS and 10 μg/ml polybrene, followed by an additional 24–
48 h of incubation. Luciferase activity was determined 48–72 h after
infection with a microtiter plate luminometer (HARTA, Inc., Gaithers-
burg, MD) using assay reagents from Promega, Inc. (Madison, WI).
Geometric mean titers for 50% neutralization (GMT50) were deter-
mined by interpolation from neutralization curves and are averages of
at least two independent assays.
A second psV neutralization assay was performed as previously
described (Li et al., 2005; Seaman et al., 2007). Similar to the U87
assay described above, two-fold serial dilutions of heat-inactivated
sera were prepared starting at a dilution of 1:20. The serum/psV
mixtures were then incubated with the TZM.bl target cells and
luciferase activity measured 48 h later. A pool of prebleed sera were
tested as negative controls, and all sera were also tested against the
521M. Totrov et al. / Virology 405 (2010) 513–523negative control psV carrying the envelope of murine leukemia virus
(MuLV).
Neutralization of HIV primary isolates
Neutralization of primary isolates grown in human PBMCs was
measured as the reduction in luc reporter gene expression after a
single round of virus infection using TZM-bl cells as previously
described (Zolla-Pazner et al., 2008)(Li et al., 2005). Brieﬂy, 200
TCID50 of virus were incubated with various dilutions of test serum
samples for 1 h at 37 °C in a total volume of 150 μl of growth medium
in 96-well ﬂat-bottom culture plates. Freshly trypsinized cells (1×104
cells) were added to each well and maintained in culture medium
containing 1 μM indinavir sulfate and also containing DEAE-dextran
(25 μg/ml)when needed for efﬁcient viral growth. Controls contained
cells only and cells plus virus. After a 48-h incubation, 50 μl of Bright
Glo reagent (Promega, Madison, WI) was added, and after a 2-min
incubation, well contents were transferred to 96-well black solid
plates, and luminescence was measured. The percent neutralization
was calculated relative to the effect of preimmune serum from the
same rabbit at the same dilution. The 50% neutralizing titers (NT50)
were determined using the method of least squares.
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